RU2502799C2 - Способ перепрограммирования соматических клеток - Google Patents

Способ перепрограммирования соматических клеток Download PDF

Info

Publication number
RU2502799C2
RU2502799C2 RU2009140903/10A RU2009140903A RU2502799C2 RU 2502799 C2 RU2502799 C2 RU 2502799C2 RU 2009140903/10 A RU2009140903/10 A RU 2009140903/10A RU 2009140903 A RU2009140903 A RU 2009140903A RU 2502799 C2 RU2502799 C2 RU 2502799C2
Authority
RU
Russia
Prior art keywords
cell
cells
oct
exogenously
proteins
Prior art date
Application number
RU2009140903/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2009140903A (ru
Inventor
Рудольф ДЖЭНИШ
Джейкоб ХАННА
Мариус ВЕРНИГ
Кристофер Дж. ЛЕНГНЕР
Александр МАЙССНЕР
Оливер Тобиас БРЭМБРИНК
Рут ФОРМАН
Original Assignee
Уайтхед Инститьют Фор Биомедикал Рисёч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайтхед Инститьют Фор Биомедикал Рисёч filed Critical Уайтхед Инститьют Фор Биомедикал Рисёч
Publication of RU2009140903A publication Critical patent/RU2009140903A/ru
Application granted granted Critical
Publication of RU2502799C2 publication Critical patent/RU2502799C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0273—Cloned vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
RU2009140903/10A 2007-04-07 2008-04-07 Способ перепрограммирования соматических клеток RU2502799C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US92212107P 2007-04-07 2007-04-07
US60/922,121 2007-04-07
US95934107P 2007-07-12 2007-07-12
US60/959,341 2007-07-12
US3606508P 2008-03-12 2008-03-12
US61/036,065 2008-03-12
PCT/US2008/004516 WO2008124133A1 (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Publications (2)

Publication Number Publication Date
RU2009140903A RU2009140903A (ru) 2011-05-20
RU2502799C2 true RU2502799C2 (ru) 2013-12-27

Family

ID=39831277

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009140903/10A RU2502799C2 (ru) 2007-04-07 2008-04-07 Способ перепрограммирования соматических клеток

Country Status (9)

Country Link
US (5) US9382515B2 (https=)
EP (3) EP2145000A4 (https=)
JP (8) JP2010523117A (https=)
CN (2) CN105861443A (https=)
AU (1) AU2008236629B2 (https=)
CA (2) CA3071055A1 (https=)
MX (2) MX348010B (https=)
RU (1) RU2502799C2 (https=)
WO (1) WO2008124133A1 (https=)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
CA2610265A1 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
CA2617611A1 (en) 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
CN105861443A (zh) 2007-04-07 2016-08-17 怀特黑德生物医学研究所 体细胞重编程
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
ES2799897T3 (es) 2007-08-31 2020-12-22 Whitehead Inst Biomedical Res Estimulación de la vía wnt en la reprogramación de células somáticas
EP2224940A1 (en) * 2007-11-30 2010-09-08 Cytomatrix PTY LTD Methods of inducing pluripotency involving oct4 protein
US20110190729A1 (en) * 2007-11-30 2011-08-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
JP5626619B2 (ja) * 2008-12-08 2014-11-19 国立大学法人京都大学 効率的な核初期化方法
JP5558097B2 (ja) * 2007-12-10 2014-07-23 国立大学法人京都大学 効率的な核初期化方法
KR20110019727A (ko) * 2008-04-07 2011-02-28 뉴포텐셜, 인크. Ｒｎａ 간섭을 통한 다능 유전자의 유도에 의한 세포 재프로그래밍
US20100279404A1 (en) 2008-05-02 2010-11-04 Shinya Yamanaka Method of nuclear reprogramming
EP3231869A1 (en) 2008-06-13 2017-10-18 Whitehead Institute for Biomedical Research Programming and reprogramming of cells
CN102144027B (zh) * 2008-07-07 2016-04-06 宝生物工程株式会社 生产多能干细胞的方法
JPWO2010027062A1 (ja) * 2008-09-04 2012-02-02 独立行政法人理化学研究所 Ｂ細胞由来ｉＰＳ細胞およびその用途
US20100062534A1 (en) * 2008-09-09 2010-03-11 The General Hospital Corporation Inducible lentiviral vectors for reprogramming somatic cells
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
CN102245588B (zh) 2008-12-23 2016-05-04 塞格提斯有限公司 缩酮酰胺化合物、其制备方法及应用
WO2010098419A1 (en) * 2009-02-27 2010-09-02 Kyoto University Novel nuclear reprogramming substance
US9487756B2 (en) * 2009-03-20 2016-11-08 Mesoblast, Inc. Production of reprogrammed pluripotent cells
CN101580816B (zh) * 2009-04-23 2012-02-29 中国科学院广州生物医药与健康研究院 诱导多能性干细胞快速高效产生的新型无血清培养基以及使用其的方法
WO2010124290A2 (en) * 2009-04-24 2010-10-28 Whitehead Institute For Biomedical Research Compositions and methods for deriving or culturing pluripotent cells
AU2010271249B2 (en) 2009-07-09 2016-01-28 Whitehead Institute For Biomedical Research Compositions and methods for mammalian genetics and uses thereof
JP5709015B2 (ja) 2009-08-19 2015-04-30 国立大学法人大阪大学 角膜移植用シート
WO2011031568A2 (en) 2009-08-27 2011-03-17 Synaptic Research, Llc A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS
EP2494032A4 (en) 2009-10-29 2013-06-05 Univ Mcmaster GENERATION OF INDUCED PLURIPOTENTER STEM CELLS AND FIBROBLAST PRECURSOR CELLS
WO2011079307A2 (en) * 2009-12-23 2011-06-30 The Salk Institute For Biological Studies Methods and compositions for treating neurological disorders
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9089520B2 (en) * 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CA2806858C (en) 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
JP2013545439A (ja) 2010-09-17 2013-12-26 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 多能性幹細胞の有用性および安全性の特徴決定を行うための機能的ゲノミクスアッセイ
JP5888753B2 (ja) 2010-11-04 2016-03-22 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
US9506039B2 (en) 2010-12-03 2016-11-29 Kyoto University Efficient method for establishing induced pluripotent stem cells
JP6273842B2 (ja) * 2011-02-25 2018-02-07 学校法人慶應義塾 ｉＰＳ細胞クローンの選択方法、及びその選択方法に用いる遺伝子の選択方法
CN102731653B (zh) * 2011-04-06 2013-12-11 李凌松 一种抗磷酸化Oct4蛋白的抗体及其应用
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
AU2012347919B2 (en) 2011-12-05 2017-02-02 Factor Bioscience Inc. Methods and products for transfecting cells
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
CN104781396A (zh) * 2012-01-17 2015-07-15 小利兰·斯坦福大学托管委员会 用于体细胞核重编程的先天免疫激活
SG11201407768QA (en) 2012-04-24 2015-01-29 Brigham & Womens Hospital Generating pluripotent cells de novo
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
WO2014057997A1 (ja) 2012-10-09 2014-04-17 Hayashi Nakanobu 初期化ペプチド及びその用途
EP2912178B1 (en) 2012-10-25 2020-06-17 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
KR102121086B1 (ko) 2012-11-01 2020-06-09 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
CA2895791A1 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
JP6456350B2 (ja) * 2013-03-11 2019-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス
HK1220233A1 (zh) 2013-03-15 2017-04-28 怀特黑德生物医学研究院 用於神经变性疾病的细胞性发现平台
CN105531365A (zh) 2013-04-23 2016-04-27 耶达研究及发展有限公司 分离的幼稚多能干细胞和产生所述细胞的方法
ES2791598T3 (es) 2013-06-05 2020-11-05 Bellicum Pharmaceuticals Inc Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa
US11085067B2 (en) 2013-06-10 2021-08-10 President And Fellows Of Harvard College Early developmental genomic assay for characterizing pluripotent stem cell utility and safety
WO2015037535A1 (ja) 2013-09-12 2015-03-19 株式会社カネカ 人工多能性幹細胞の分化誘導方法及び選別方法
WO2015069736A1 (en) 2013-11-08 2015-05-14 The Mclean Hospital Corporation METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
EP3099801B1 (en) 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
ES2895941T3 (es) 2014-02-10 2022-02-23 Univ Leland Stanford Junior Activación de la inmunidad innata para una reprogramación nuclear mejorada de células somáticas con ARNm
KR102327986B1 (ko) 2014-03-19 2021-11-18 브이셀 세라퓨틱스 인코포레이티드 다능성 세포에 관한 방법
CN108064274A (zh) 2014-07-30 2018-05-22 耶达研究及发展有限公司 用于培养多能干细胞的培养基
EP3191578B1 (en) 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Cells expressing apolipoprotein e and uses thereof
EP4494699A3 (en) 2014-10-03 2025-04-30 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US20180112180A1 (en) 2015-01-26 2018-04-26 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10961532B2 (en) * 2015-04-07 2021-03-30 The General Hospital Corporation Methods for reactivating genes on the inactive X chromosome
CA3019311A1 (en) 2015-04-15 2016-10-20 University Of Massachusetts Compositions and methods for xi chromosome reactivation
US20170044609A1 (en) * 2015-04-24 2017-02-16 California Institute Of Technology Reactivation of x chromosome genes
US11249071B2 (en) 2015-04-24 2022-02-15 California Institute Of Technology Reactivation of x chromosome genes
US20180214487A1 (en) 2015-07-21 2018-08-02 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses
US10662409B2 (en) * 2015-09-09 2020-05-26 Trustees Of Tufts College Methods of generating neural stem cells
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CN105624117A (zh) * 2016-01-18 2016-06-01 哈尔滨医科大学 一种低氧促进小鼠成纤维细胞重编程为心肌细胞的方法
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US20170369904A1 (en) * 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
CA3034369A1 (en) 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
CN106544315A (zh) * 2016-10-12 2017-03-29 广东艾时代生物科技有限责任公司 一种脂肪间充质干细胞诱导成多能干细胞的方法
EP3532044A4 (en) 2016-10-27 2020-07-29 California Institute of Technology HDAC INHIBITOR COMPOSITIONS FOR CHROMOSOME X REACTIVATION
CN110402284B (zh) 2016-12-16 2024-03-08 伊维瓦医疗有限公司 用于基底膜支架的薄膜插入
DK3565891T3 (da) 2017-01-09 2023-07-24 Whitehead Inst Biomedical Res Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer
EP3591040A4 (en) 2017-03-03 2020-11-11 Kyoto University METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS
WO2018185709A1 (en) * 2017-04-05 2018-10-11 Centro De Neurociencias E Biologia Celular Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
US20200208093A1 (en) 2017-06-14 2020-07-02 Takeda Pharmaceutical Company Limited Cell-sealing device
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
PL241125B1 (pl) 2017-11-30 2022-08-08 Gdanski Univ Medyczny Kompozycja farmaceutyczna do zastosowania jako środek do pobudzania regeneracji lub gojenia ran
MX2020005668A (es) 2017-11-30 2020-11-24 Univ Kyoto Metodo de cultivo de celulas.
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CN111868224A (zh) 2017-12-22 2020-10-30 国立大学法人京都大学 细胞培养装置，培养液抽吸器及细胞培养方法
CN108624621B (zh) * 2018-01-17 2019-04-12 中国科学院上海生命科学研究院 非人灵长类的体细胞克隆动物的制备方法
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
CN111868235A (zh) 2018-03-19 2020-10-30 国立大学法人京都大学 水凝胶胶囊
EP3778902A4 (en) 2018-03-30 2021-12-29 Kyoto University Cell production method
JP7344486B2 (ja) 2018-03-30 2023-09-14 国立大学法人京都大学 心筋細胞成熟促進剤
AU2019241702B2 (en) 2018-03-30 2023-07-27 Orizuru Therapeutics, Inc Heterocyclic compound
JP6779509B2 (ja) 2018-04-23 2020-11-04 国立大学法人京都大学 増殖抑制剤
EP3831931B1 (en) 2018-08-03 2025-04-09 Orizuru Therapeutics, Inc. Cell production method
CN112567025B (zh) 2018-08-10 2025-01-17 国立大学法人京都大学 Cd3阳性细胞的制造方法
EP3842538A4 (en) 2018-08-10 2022-06-08 Kyoto University METHOD OF TRANSFECTION INTO CARDIOMYOCYTES USING CATIONIC LIPID
WO2020040166A1 (ja) 2018-08-22 2020-02-27 国立大学法人京都大学 腸管神経前駆細胞の製造方法
CN112771166B (zh) 2018-08-31 2025-03-04 诺伊尔免疫生物科技株式会社 表达car的t细胞和car表达载体
WO2020059892A1 (ja) 2018-09-19 2020-03-26 武田薬品工業株式会社 インスリン産生細胞
US12097239B2 (en) 2018-09-21 2024-09-24 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching MRNA coding for secreted proteins
EP3868869A4 (en) 2018-10-15 2022-08-03 Public University Corporation Yokohama City University NUTRITIONAL COMPOSITION
CN113272319A (zh) 2018-12-27 2021-08-17 国立大学法人京都大学 T细胞受体的变体
WO2020150391A1 (en) * 2019-01-15 2020-07-23 Falcon Therapeutics, Inc. Engineered stem cell constructs and uses thereof
JP7508045B2 (ja) 2019-02-01 2024-07-01 国立大学法人京都大学 細胞の検出方法
WO2020204149A1 (ja) 2019-03-29 2020-10-08 公立大学法人横浜市立大学 スクリーニング方法および毒性評価法
JP7630830B2 (ja) 2019-04-10 2025-02-18 オリヅルセラピューティクス株式会社 生体組織様構造体の製造方法
EP3969571A4 (en) 2019-05-14 2023-05-24 Aleph Farms Ltd. PLURIPOTENTE CELL AGGREGATES AND THEIR USE
WO2020250913A1 (ja) 2019-06-11 2020-12-17 国立大学法人京都大学 腎間質細胞の製造方法
CA3145425A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP4019549B1 (en) 2019-08-20 2025-06-04 Orizuru Therapeutics, Inc. Method for enriching cardiac myocytes
CA3158631A1 (en) 2019-10-21 2021-04-29 Orizuru Therapeutics, Inc. Growth inhibitor
EP4053267A4 (en) 2019-11-01 2024-03-20 Kyoto University Method for producing t cell
CA3162755A1 (en) 2019-11-25 2021-06-03 Kyoto University T-cell master cell bank
BR112022018640A2 (pt) 2020-03-19 2022-11-08 Orizuru Therapeutics Inc Métodos para produzir uma população de células compreendendo cardiomiócitos e para purificar cardiomiócitos, população de células contendo cardiomiócitos, e, agente para terapia de transplante de células
EP4123016A4 (en) 2020-03-19 2024-06-19 Orizuru Therapeutics, Inc. Method for purifying cardiomyocytes
JPWO2021200901A1 (https=) 2020-03-31 2021-10-07
JPWO2021241668A1 (https=) 2020-05-28 2021-12-02
CN112201307B (zh) * 2020-09-23 2024-09-17 温州医科大学 一种转录本注释方法以及筛选长非编码rna和内源逆转录病毒来源长非编码rna的方法
JP7805009B2 (ja) 2020-11-20 2026-01-23 オリヅルセラピューティクス株式会社 成熟化剤
TW202246489A (zh) 2021-02-09 2022-12-01 日商千紙鶴治療公司 成熟化劑
WO2022191171A1 (ja) 2021-03-09 2022-09-15 国立大学法人 東京医科歯科大学 細胞クラスターの製造方法
US20240191192A1 (en) 2021-04-08 2024-06-13 Takeda Pharmaceutical Company Limited Method for activating t-cells
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
CN117242171A (zh) 2021-04-28 2023-12-15 国立大学法人东京医科齿科大学 用于产生细胞的方法
CN113278686A (zh) * 2021-06-11 2021-08-20 扬州大学 一种研究dna甲基化调控重编程过程的方法
AU2022349176A1 (en) 2021-09-27 2024-04-11 Kyoto University Method for producing t cell
US20250195655A1 (en) 2022-02-04 2025-06-19 Kyoto University T cell production method
CN119256076A (zh) 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法
AU2023262842A1 (en) 2022-04-25 2024-09-12 Orizuru Therapeutics, Inc. Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
US20250332259A1 (en) 2022-06-17 2025-10-30 Kyoto University Thymic epithelial cell production method
WO2024014497A1 (ja) 2022-07-14 2024-01-18 オリヅルセラピューティクス株式会社 細胞移植用のフィブリンゲルシート
EP4563697A4 (en) 2022-07-25 2025-11-12 Univ Kyoto IN VITRO CULTURE METHOD FOR INDUCING OVARIAN FOLLICLES FROM PRIMATE FETAL OVARIAN CELLS
WO2024024551A1 (ja) 2022-07-26 2024-02-01 国立大学法人京都大学 シェディング構造を有する人工受容体
EP4567105A1 (en) 2022-08-05 2025-06-11 Kyoto University Method for producing cardiac muscles
WO2024034559A1 (ja) 2022-08-08 2024-02-15 株式会社ヘリオス 細胞凝集塊の製造方法
WO2024050517A1 (en) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Methods of making and using anticancer reprogrammed b cells
EP4600352A1 (en) 2022-09-26 2025-08-13 Kyoto University T cell production method
US20260097083A1 (en) 2022-09-26 2026-04-09 Kyoto University Method for producing pancreatic endoderm cells
WO2024071280A1 (ja) 2022-09-29 2024-04-04 国立大学法人京都大学 腎毒性評価方法
EP4620480A1 (en) 2022-11-16 2025-09-24 Kansai Medical University Educational Corporation Implantation facilitator, and screening system therefor
AU2024232721A1 (en) 2023-03-03 2025-10-09 Kyoto University Method for producing primed pluripotent stem cells
JPWO2024242069A1 (https=) 2023-05-19 2024-11-28
CN121646636A (zh) 2023-06-02 2026-03-10 国立大学法人京都大学 T细胞祖细胞产生方法
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025037497A1 (ja) 2023-08-15 2025-02-20 国立大学法人京都大学 小腸組織の製造方法
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025106897A1 (en) * 2023-11-16 2025-05-22 Colossal Biosciences Inc. Methods and compositions for creating induced pluripotent stem cells
WO2025260068A1 (en) 2024-06-14 2025-12-18 Tune Therapeutics, Inc. Lipid nanoparticle formulation for delivery of nucleic acids to cells
WO2026015647A1 (en) 2024-07-09 2026-01-15 Tune Therapeutics, Inc. Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2249039C2 (ru) * 1999-02-04 2005-03-27 Текнион Рисерч Энд Дивелопмент Фаундейшн Лтд. Способ размножения/поддержания недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты), способ приготовления кондиционированной среды стромальных клеток, способ трансплантации недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты)
US20070032447A1 (en) * 2005-08-01 2007-02-08 Eilertsen Kenneth J Production of reprogrammed cells with restored potential

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US4846835A (en) 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
JPH09500534A (ja) * 1993-07-22 1997-01-21 メルク エンド カンパニー インコーポレーテッド トランスジェニック動物でのヒトインターロイキン―１βの発現
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5698446A (en) 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9517779D0 (en) * 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9809178D0 (en) 1998-04-29 1998-07-01 Univ Edinburgh Nuclear reprogramming of somatic cells
US6875607B1 (en) 1998-11-09 2005-04-05 Es Cell International Pte Ltd Embryonic stem cells
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
AU2002242173A1 (en) 2001-02-15 2002-08-28 Whithead Institute For Biomedical Research Stem cell identification
US20020137460A1 (en) * 2001-03-08 2002-09-26 Howard Sun Universal multi-band (5 bands and more) keyless RF remote control unit using bluetooth radio module as the base
JP4183614B2 (ja) 2001-05-31 2008-11-19 伸弥 山中 Ｅｓ細胞特異的発現遺伝子
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
EP1437403A4 (en) 2001-09-21 2004-10-27 Japan Science & Tech Corp METHOD FOR PATTERNING REPROGRAMMING FACTOR, METHOD OF PATTERNED REPROGRAMMING FACTOR, METHOD FOR USE OF REPROGRAMMING FACTOR, METHOD FOR DIFFERENTIATING AND SIFE-INGENATING FAN
DE10162080A1 (de) * 2001-12-10 2003-06-26 Albrecht Mueller Verfahren zur Herstellung von Stammzellen mit erhöhtem Entwicklungspotential
GB0202149D0 (en) * 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0211904D0 (en) * 2002-05-23 2002-07-03 Medical Res Council Nuclear transfer
CA2493768A1 (en) 2002-07-23 2004-01-29 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
WO2005001080A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US7682828B2 (en) * 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
JP4901471B2 (ja) * 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
EP1574499A1 (en) 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
KR101178786B1 (ko) * 2004-03-23 2012-09-07 다이이찌 산쿄 가부시키가이샤 다능성 줄기세포의 증식 방법
WO2006050257A2 (en) 2004-10-29 2006-05-11 Massachusetts Institute Of Tecchnology Detection of ion channel or receptor activity
NZ563603A (en) * 2005-04-29 2010-10-29 Innovative Dairy Products Pty A method for producing stem cells or stem cell-like cells from mammalian embryos
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0615327D0 (en) * 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
EP2038247A4 (en) 2006-06-27 2011-08-17 Jncasr Bangalore Site-specific inhibitors of histone metyltransferase [HMTASE] and method for their preparation
JP5813321B2 (ja) * 2007-03-23 2015-11-17 ウィスコンシン アラムニ リサーチ ファンデーション 体細胞の再プログラム化
CN105861443A (zh) 2007-04-07 2016-08-17 怀特黑德生物医学研究所 体细胞重编程
WO2009032456A2 (en) * 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
ES2799897T3 (es) * 2007-08-31 2020-12-22 Whitehead Inst Biomedical Res Estimulación de la vía wnt en la reprogramación de células somáticas
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
WO2009115295A1 (en) 2008-03-17 2009-09-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
MX2010010165A (es) 2008-03-17 2010-11-25 Scripps Research Inst Procedimientos quimicos y geneticos combinados para generacion de celulas madre pluripotentes inducidas.
US20100279404A1 (en) 2008-05-02 2010-11-04 Shinya Yamanaka Method of nuclear reprogramming
EP3231869A1 (en) * 2008-06-13 2017-10-18 Whitehead Institute for Biomedical Research Programming and reprogramming of cells
WO2010033920A2 (en) 2008-09-19 2010-03-25 Whitehead Institute For Biomedical Research Compositions and methods for enhancing cell reprogramming
US20100150889A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic Vector For Human Induced Pluripotent Stem Cell Production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2249039C2 (ru) * 1999-02-04 2005-03-27 Текнион Рисерч Энд Дивелопмент Фаундейшн Лтд. Способ размножения/поддержания недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты), способ приготовления кондиционированной среды стромальных клеток, способ трансплантации недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты)
US20070032447A1 (en) * 2005-08-01 2007-02-08 Eilertsen Kenneth J Production of reprogrammed cells with restored potential

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SAVARESE ЕТ AL.: 'Hematopoietic Precursor Cells Transiently Reestablish Permissiveness for X inactivation' MOLECULAR AND CELLULAR BIOLOGY vol. 26, no. 19, October 2006, pages 7167-7177. *
TAKAHASHI K. ЕТ AL.: 'Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors' CELL vol. 126, no. 4, 25 August 2006, pages 663-676. *
TAKAHASHI K. ЕТ AL.: 'Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors' CELL vol. 126, no. 4, 25 August 2006, pages 663-676. SAVARESE ЕТ AL.: 'Hematopoietic Precursor Cells Transiently Reestablish Permissiveness for X inactivation' MOLECULAR AND CELLULAR BIOLOGY vol. 26, no. 19, October 2006, pages 7167-7177. *

Also Published As

Publication number Publication date
EP2626416A3 (en) 2013-12-18
US9382515B2 (en) 2016-07-05
JP2020014479A (ja) 2020-01-30
EP2145000A1 (en) 2010-01-20
JP2020014480A (ja) 2020-01-30
US20110076678A1 (en) 2011-03-31
CA2683056C (en) 2020-03-24
US9714414B2 (en) 2017-07-25
JP2015051022A (ja) 2015-03-19
US20150118755A1 (en) 2015-04-30
MX2009010847A (es) 2010-04-27
AU2008236629B2 (en) 2014-03-06
WO2008124133A1 (en) 2008-10-16
JP2017035113A (ja) 2017-02-16
US20170342386A1 (en) 2017-11-30
JP2010523117A (ja) 2010-07-15
CA2683056A1 (en) 2008-10-16
CA3071055A1 (en) 2008-10-16
CN101932705A (zh) 2010-12-29
RU2009140903A (ru) 2011-05-20
US10093904B2 (en) 2018-10-09
MX348010B (es) 2017-05-23
US20190241874A1 (en) 2019-08-08
AU2008236629A1 (en) 2008-10-16
EP3878949B1 (en) 2025-06-04
EP2626416A2 (en) 2013-08-14
CN105861443A (zh) 2016-08-17
EP2145000A4 (en) 2010-05-05
JP6934501B2 (ja) 2021-09-15
MX352541B (es) 2017-11-29
JP2022031941A (ja) 2022-02-22
JP2024024049A (ja) 2024-02-21
EP3878949A1 (en) 2021-09-15
US20250188423A1 (en) 2025-06-12
JP2018086017A (ja) 2018-06-07

Similar Documents

Publication Publication Date Title
RU2502799C2 (ru) Способ перепрограммирования соматических клеток
Patel et al. Advances in reprogramming somatic cells to induced pluripotent stem cells
Mao et al. Reprogramming stem cells in regenerative medicine
Abou-Saleh et al. The march of pluripotent stem cells in cardiovascular regenerative medicine
JP2017035113A5 (https=)
Hu All roads lead to induced pluripotent stem cells: the technologies of iPSC generation
Cheng et al. Protecting against wayward human induced pluripotent stem cells with a suicide gene
Kramer et al. Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury
ES2900277T3 (es) Producción de células pluripotentes reprogramadas
US12404507B2 (en) Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases
JP7579935B2 (ja) Ｃｒｉｓｐｒ活性化による人工多能性細胞の生成
WO2012079278A1 (zh) 诱导性多能干细胞的制备方法以及用于制备诱导性多能干细胞的培养基
Anastasia et al. Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine
US20260117185A1 (en) Enhancement of fibroblast plasticity for treatment of disc degeneration
US20090180996A1 (en) Epigenetic modification of cell phenotype, fate and/or function by RNA transfer
Wang et al. Reprogramming of mouse renal tubular epithelial cells to induced pluripotent stem cells
WO2013004135A1 (zh) 诱导性多能干细胞的制备方法和用于制备诱导性多能干细胞的培养基
Guillot Induced pluripotent stem (iPS) cells from human fetal stem cells
Kuzma-Hunt et al. Opening the “black box” underlying barriers to the use of canine induced pluripotent stem cells: a narrative review
Petersen et al. Generation of diverse neural cell types through direct conversion
Ramesh et al. Somatic cell dedifferentiation/reprogramming for regenerative medicine
Batubara Induced pluripotent stem cells and genome editing technology as therapeutic strategies for Duchenne muscular dystrophy
Heng et al. Induced adult stem (iAS) cells and induced transit amplifying progenitor (iTAP) cells—a possible alternative to induced pluripotent stem (iPS) cells?
Parameswarana et al. Non-Cell Autonomous Reprogramming: a Nucleic Acid Free Approach to Induction of Pluripotency
Chronowska Induced pluripotent stem (iPS) cells in domestic animals-recent achievements-a review.